MAIA Biotechnology, Inc. (MAIA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US5526411021
MAIA Biotechnology, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -24.27 m USD |
| EBIT | -22.39 m USD |
| Net income | -22.40 m USD |
| Diluted EPS – continuing operations | -0.70 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
More stocks
- NETSOL TECHNOLOGIES INC (NTWK)
- Concorde International Group Ltd Class A Ordinary Shares (CIGL)
- WRAP TECHNOLOGIES, INC. (WRAP)
- Richmond International Travel & Tours Co Ltd (2743.TWO)
- Sangsangin Investment & Securities Co Ltd (001290.KS)
- Korea Pharmacy Co. Ltd. (032300.KQ)
- Crown Confectionery Co Ltd (264900.KS)
- Viskase Holdings, Inc. (VISK)
- WASGAU Produktions & Handels AG (MSH.F)
- Union Auction Public Company Limited (AUCT.BK)
- Wavice Inc. (289930.KQ)
- Complex Micro Interconnection Co. Ltd. (6835.TW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.